Our Current Trials

A Phase 1/2 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

This Phase 1/2 trial is currently recruiting patients ages 7 years and older.

Learn more

A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

This Phase 1/2 trial is currently recruiting adult patients.

Learn more